Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients on Disease-Modifying Drugs
Not Applicable
- Conditions
- Multiple Sclerosis
- Registration Number
- JPRN-UMIN000049478
- Lead Sponsor
- Osaka University Department of Neurology, Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Has been infected with SARS-CoV-2 virus up to 3 months after the second mRNA vaccination against SARS-CoV-2. Known allergy or contraindication to any vaccine component. Has received treatment with another vaccine within 4 weeks of the first SARS-CoV-2 mRNA vaccine. Participating in another clinical trial. Has used steroids within 3 months of the first SARS-CoV-2 mRNA vaccine and within 3 months of the second dose. Received intravenous or subcutaneous immunoglobulin (IVIG/SCIG) within 3 months after the first or second dose of SARS-CoV-2 mRNA vaccine. Other cases in which the attending physician deems it inappropriate.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method